Median Technologies Reports Results from the REALITY Trial of Eyonis LCS for Lung Cancer Diagnosis
Shots:
- The pivotal REALITY trial evaluated eyonis LCS’s ability to distinguish b/w cancerous & non-cancerous patients as well as suspicious & malignant nodules. It studied data from patients (n=1,147) for lung cancer diagnosis across the US & EU
- Trial reached its 1EP & all 2EPs, depicting efficient cancerous nodules detection and an AUC value of 0.904 at patient level (min. value was 0.80 as 1EP). Identification included difficult-to-diagnose stage 1 cancers (80%) plus, cases such as small non-spiculated cancers & large spiculated benign nodules
- Another pivotal RELIVE study is underway to confirm the REALITY study data. Study is set to finish in upcoming mos., with data expected in Q1’25 & regulatory filings in H1’25
Ref: Median Technologies | Image: Median Technologies
Related News:- GSK’s GSK5764227 (GSK’227) Gets the US FDA’s Breakthrough Therapy Designation for r/r Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
